Do MSI-L Sporadic Colorectal Tumors Develop Through “Mild Mutator Pathway”?

Abstract

We believe that MSI-L tumors could be considered a distinct phenotype that develops through a "mild mutator pathway."

Sporadic colorectal carcinomas with low‐level microsatellite instability in Korea: Do they form a distinct subgroup with distinguished clinicopathological features?

“…There have been several studies reporting the comparable prognosis of MSI-low CRCs to MSS CRCs, which was consistent with our results [10,18]. In contrast to these results, two recent studies reported that MSI-low CRCs might have poorer prognosis in stage C CRCs compared with MSS CRCs [15,16].…”

“…There have been conflicting data on whether MSI-low CRCs displayed distinguished clinicopathological or molecular features and formed a distinct subgroup from MSS or MSI-high CRCs [1,2,[5][6][7][8][9][10][11][12][13]17,18]. However, recent molecular and clinical studies favoured the existence of MSI-low CRCs as a distinct subgroup.…”

“…In addition, most non-MSI-high CRCs in these studies could be classified as MSI-low CRCs when a large enough number of MSI markers was examined [8,9]. However, some other studies reported the data supporting the existence of MSI-low CRCs as a biologically distinct subgroup [11][12][13][14][15][16][17][18]. Jass and his colleagues reported that MSI-low CRCs demonstrated lower frequency of 5q loss of heterozygosity and higher frequency of K-ras mutation and O…”

Exploration into Plasma Hsa_circ_0052184 as a New Biomarker of Colorectal Cancer Prognosis

“…20 Moreover, TP53 mutation has been found in about 43% of sporadic CRC cases (IARC TP53 database; https://p53.iarc.fr), and MSI-L CRC patients show higher incidence of KRAS mutations. 21 Thus, screening for defective, DNA mismatch repair in CRC patients should include immunohistochemistry (IHC) and/or MSI test. 22,23 However, Serum biomarker identification is among the most ambitious pursuits of the current oncologic research.…”